Cannabis Science and Technology January/February 2025 Interactive Digital Edition

Avecho and Sandoz have signed an exclusive license and development agreement to commercialize CBD for use with insomnia in Australia.

In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.

A recent study showed that retail cannabis sales may play a role in reducing drinking seen with young adults.

In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.

This webinar covered how cannabis for this neurodegenerative disease could provide better symptom relief and improve quality of life better than conventional treatments.

The Alabama Medical Cannabis Commission made the announcement in its most recent meeting, intending to advance the state medical cannabis program.